A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

NCT05538572 PHASE1 COMPLETED

This is a Phase 1 dose-escalation study of PRT3645, a Cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor, in patients with advanced or metastatic solid tumors. The purpose of this study is to investigate the safety, tolerability, dose limiting toxicity, and to determine maximally tolerated dose and recommended phase 2 dose to be used in subsequent development of PRT3645.

Details

Lead sponsor	Prelude Therapeutics
Phase	PHASE1
Status	COMPLETED
Enrolment	22
Start date	Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jun 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Breast Cancer
• Glioblastoma
• Head and Neck Squamous Cell Carcinoma
• Malignant Mesothelioma
• Non-small Cell Lung Cancers
• Sarcoma
• Endometrial Cancer

Interventions

• PRT3645

Countries

Singapore, United States